Literature DB >> 20458340

The role of echocardiographic deformation imaging in hypertrophic myopathies.

Maja Cikes1, George R Sutherland, Lisa J Anderson, Bart H Bijnens.   

Abstract

Echocardiography has a leading role in the routine assessment and diagnosis of hypertrophic ventricles. However, the use of M-mode echocardiography and measurement of global left ventricular function may be misleading. Traditionally, systolic function was thought to be preserved in patients with hypertrophic myopathies until the late stages of the disease, and hypertrophic myopathies were thought to affect the myocardium more diffusely than ischemic heart disease. Ultrasound deformation imaging, either by Doppler myocardial imaging or speckle tracking, provides more-sensitive detection of regional myocardial motion and deformation than standard echocardiography. Basic and clinical studies that apply these techniques have revealed early, often subclinical impairment in systolic function. This information allows the detection and treatment of myocardial dysfunction at an early stage, which is of high clinical importance. Physiological hypertrophic remodeling seen in athletes differs from pathological myocardial hypertrophy, which can be caused by compensatory reactive hypertrophy owing to pressure overload in patients with aortic stenosis or hypertension, as well as amyloidosis, Fabry disease or Friedreich ataxia. Each of the etiologies associated with hypertrophy demonstrate distinct regional changes in myocardial deformation, which allows identification of the underlying processes, and will improve the assessment and follow-up of patients with hypertrophic myopathies.

Entities:  

Mesh:

Year:  2010        PMID: 20458340     DOI: 10.1038/nrcardio.2010.56

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  132 in total

1.  Quantification of regional right and left ventricular function by ultrasonic strain rate and strain indexes in Friedreich's ataxia.

Authors:  Frank Weidemann; Benedicte Eyskens; Luc Mertens; Giovanni Di Salvo; Jörg Strotmann; Gunnar Buyse; Piet Claus; Jan D'hooge; Bart Bijnens; Marc Gewillig; George R Sutherland
Journal:  Am J Cardiol       Date:  2003-03-01       Impact factor: 2.778

2.  Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy.

Authors:  G P Aurigemma; K H Silver; M A Priest; W H Gaasch
Journal:  J Am Coll Cardiol       Date:  1995-07       Impact factor: 24.094

3.  Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; T J Anan; W C Roberts
Journal:  Circulation       Date:  1981-04       Impact factor: 29.690

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

Review 5.  Cardiovascular adaptations to physical training.

Authors:  C G Blomqvist; B Saltin
Journal:  Annu Rev Physiol       Date:  1983       Impact factor: 19.318

6.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

Review 7.  The usefulness of Doppler myocardial imaging in the study of the athlete's heart and in the differential diagnosis between physiological and pathological ventricular hypertrophy.

Authors:  Antonello D'Andrea; Luigi D'Andrea; Pio Caso; Marino Scherillo; Paolo Zeppilli; Raffaele Calabrò
Journal:  Echocardiography       Date:  2006-02       Impact factor: 1.724

Review 8.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

9.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

10.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

View more
  26 in total

1.  Left ventricular adaptation to high altitude: speckle tracking echocardiography in lowlanders, healthy highlanders and highlanders with chronic mountain sickness.

Authors:  Chantal Dedobbeleer; Alia Hadefi; Aurelien Pichon; Francisco Villafuerte; Robert Naeije; Philippe Unger
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-10       Impact factor: 2.357

2.  Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study.

Authors:  Geneviève Giraldeau; Nicolas Duchateau; Bart Bijnens; Luigi Gabrielli; Diego Penela; Reinder Evertz; Lluis Mont; Josep Brugada; Antonio Berruezo; Marta Sitges
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-04       Impact factor: 2.357

3.  Magnetic Resonance Imaging of Cardiac Strain Pattern Following Transplantation of Human Tissue Engineered Heart Muscles.

Authors:  Xulei Qin; Johannes Riegler; Malte Tiburcy; Xin Zhao; Tony Chour; Babacar Ndoye; Michael Nguyen; Jackson Adams; Mohamed Ameen; Thomas S Denney; Phillip C Yang; Patricia Nguyen; Wolfram H Zimmermann; Joseph C Wu
Journal:  Circ Cardiovasc Imaging       Date:  2016-11       Impact factor: 7.792

Review 4.  Mechano-Immunomodulation: Mechanoresponsive Changes in Macrophage Activity and Polarization.

Authors:  Sarah Adams; Leah M Wuescher; Randall Worth; Eda Yildirim-Ayan
Journal:  Ann Biomed Eng       Date:  2019-06-19       Impact factor: 3.934

5.  Diastolic myocardial dysfunction by tissue Doppler imaging predicts mortality in patients with cerebral infarction.

Authors:  Flemming J Olsen; Peter G Jørgensen; Rasmus Møgelvang; Jan S Jensen; Thomas Fritz-Hansen; Jan Bech; Jacob Sivertsen; Tor Biering-Sørensen
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-21       Impact factor: 2.357

6.  Right- and left-ventricular strain evaluation in repaired pediatric Tetralogy of Fallot patients using magnetic resonance tagging.

Authors:  Alexander Khalaf; Donel Tani; Sameh Tadros; Shobhit Madan
Journal:  Pediatr Cardiol       Date:  2013-01-31       Impact factor: 1.655

7.  Abnormal left ventricular global strain during exercise-test in young healthy smokers.

Authors:  Giuseppe Mandraffino; Egidio Imbalzano; Alberto Lo Gullo; Concetta Zito; Carmela Morace; Maria Cinquegrani; Francesca Savarino; Lilia Oreto; Clemente Giuffrida; Scipione Carerj; Giovanni Squadrito
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

8.  Distribution of myocardial work in arterial hypertension: insights from non-invasive left ventricular pressure-strain relations.

Authors:  Bart Bijnens; Marta Sitges; Filip Loncaric; Maciej Marciniak; Loredana Nunno; Maria Mimbrero; Joao F Fernandes; Dora Fabijanovic; Laura Sanchis; Adelina Doltra; Silvia Montserrat; Maja Cikes; Pablo Lamata
Journal:  Int J Cardiovasc Imaging       Date:  2020-08-12       Impact factor: 2.357

Review 9.  Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain.

Authors:  Hidekazu Tanaka
Journal:  J Echocardiogr       Date:  2021-01-18

Review 10.  Myocardial Strain Imaging in Resistant Hypertension.

Authors:  Reem Alsharari; David Oxborough; Gregory Y H Lip; Alena Shantsila
Journal:  Curr Hypertens Rep       Date:  2021-05-05       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.